|
|
 |
|
Viewing report
|
|
|
|
The Global GCP Compliance Report 2006: US, EU, and Japan
Cambridge Healthtech Institute, Sep 2005, Pages: 180
The First-Ever Study of Global GCP Clinical Trial Compliance Programs and Trends! Learn what the FDA, EMEA, OHRP, and Japan’s PMDA see as the GCP compliance “hot spots” today! Developed for clinical sponsors and CRAs, clinical trial administrators, clinical compliance officers, clinical investigators and site staff, clinical QA professionals, and other clinical professionals!
As clinical trials are becoming more global in nature and standards for clinical trial conduct are becoming more harmonized, this just-released report presents a first-of-its kind systematic study of GCP compliance in the world’s major markets.
Gain exclusive access to detailed data analyses of GCP compliance trends internationally, profiles of GCP compliance programs within several of the world’s key regulatory agencies, and in-depth interviews with GCP compliance officials and GCP field inspectors!
Plus, gain access to the largest compendium of GCP compliance trends and data ever compiled! Learn exactly where regulators such as the FDA, EMEA, OHRP, UK MHRA, Health Canada and Japan’s PMDA are finding GCP problems, and what their GCP compliance “hot spots” are today for those sponsoring and conducting clinical trials.
In The Global GCP Compliance Report, you’ll gain access to the following in-depth profiles, compliance data, and interviews:
- FDA GCP Compliance Programs for Drugs, Biologics, and Medical Devices
- Interview with the EMEA’s GCP Compliance Administrator Fergus Sweeney, Ph.D.
- The Largest Collection of International GCP Compliance Data Anywhere
- US OHRP Compliance Program/Data for Government-sponsored Research
- UK MHRA’s GCP Compliance Program
- Japan’s PMDA’s GCP Compliance Program and Trend Data
- Interview with FDA Bioresearch Monitoring Specialist/Inspector Mike Rashti
- Interview with FDA CDRH (Devices) BIMO Director Michael Marcarelli
- Interview with FDA CBER (Biologics) BIMO Branch Chief Patricia Holobaugh
- Complete analyses of investigator, sponsor/monitor, and IRB GCP compliance deficiencies in warning letters/regulatory notifications
- An interview with FDA's CDER BIMO Director Joanne Rhoads
- An interview with Health Canada Good Clinical Practices Unit Director Jean Saint-Pierre
Customers who bought this item also bought
CFR/ICH GCP Clinical Trial Reference Guide 2009
Good Clinical Practice: A Question and Answer Reference Guide 2009
eHealth Solutions for Pharma: Strategies for Salesforces, Marketing, Patient Compliance and Clinical Trials
Streamlining Clinical Trials
Guide to Good Clinical Practice, 3rd Edition
The 2009-2014 Outlook for Governance, Risk Management, and Compliance Programs in Japan
The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors
Trends in Clinical Trials: Strategies to enhance clinical trial design
Patient Compliance
Clinical Trials in India
Health Care Fraud: Enforcement and Compliance
Creating a Compliance Program for Your Company
|
|
|
|
